Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Phase IIIb, multicenter, randomized, double-masked, sham injection-controlled...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of ophthalmology Vol. 145; no. 2; pp. 239 - 248.e5
Main Authors:	Regillo, Carl D., Brown, David M., Abraham, Prema, Yue, Huibin, Ianchulev, Tsontcho, Schneider, Susan, Shams, Naveed
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01.02.2008 Elsevier Elsevier Limited
Subjects:	Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Biological and medical sciences Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Diabetic retinopathy Double-Blind Method Drug dosages Female Humans Injections Macular degeneration Macular Degeneration - complications Macular Degeneration - drug therapy Male Medical sciences Middle Aged Miscellaneous Occult sciences Ophthalmology Ranibizumab Retinopathies Treatment Outcome Visual Acuity - drug effects Vitreous Body Retinopathy Mask Monoclonal antibody Macular degeneration Immunomodulator Eye disease Vascular endothelium growth factor Ranibizumab Clinical trial Age related macular degeneration Neovascularization Ophthalmology Antiangiogenic agent
ISSN:	0002-9394, 1879-1891
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!